Integrating HER2-Targeted Trial Data into Real-World Pathways and Managing Toxicities

This segment focuses on how clinicians translate recent HER2-targeted therapy data into practical treatment decisions and manage associated toxicities in real-world settings.

Guideline Integration and Personalized Care:
Dr. Gradishar emphasizes that guidelines like NCCN provide a framework and evidence-based sequence for therapies but are designed for populations, not individual patients. He notes that comorbidities, travel limitations, and other patient-specific factors may necessitate deviations, highlighting that "perfect can be the enemy of good." Dr. Mouabbi and Dr. Gadi reinforce this view, noting that tertiary centers have more flexibility to personalize care, whereas community practices often must strictly follow guidelines due to reimbursement considerations. NCCN guidelines are described as a "floor above which we should always be practicing," serving as a benchmark rather than a rigid rule.

Toxicity Management and Monitoring Strategies:
The discussion shifts to monitoring and managing toxicities associated with ADCs and tyrosine kinase inhibitors (TKIs). Key points include:

• Patient Education: Central to toxicity management. Patients should understand what side effects to monitor (ILD/pneumonitis, gastrointestinal (GI), ocular issues, cardiotoxicity) and report symptoms early.
• Proactive Surveillance: Rather than reacting to adverse events, clinicians should schedule proactive monitoring: echocardiograms for cardiac function, imaging for ILD detection, and baseline optometry exams for ocular side effects. Early detection allows continuation of therapy with appropriate interventions.
• Medication Management: For GI side effects (especially with TKIs), prophylactic measures such as loperamide or dose-escalation strategies can reduce severity. Low-dose olanzapine has also been highlighted as effective for nausea and vomiting.
• Salvaging Therapy: Dr. Gadi references real-world data showing that patients who temporarily stopped ADC therapy due to ILD can, in some cases, safely resume treatment, maintaining efficacy.
• Team-Based Education: Dr. Rao emphasizes that education should extend beyond patients to healthcare teams, including nurses and pharmacists, who often serve as the first point of contact for side effects.

Overall, the segment underscores that integrating trial data into practice requires balancing guideline recommendations with individualized patient factors and emphasizes a proactive, team-based approach to managing toxicities.